Fig. 6

The efficacy of Selinexor and JQ1 in primary patient cells. Cell viability assays under the influence of different concentrations of Selinexor and JQ1, respectively in patient 1# (A), patient 4# (E) and patient 5# (I). Inhibition rate heat map at different concentrations of Selinexor and JQ1, respectively in cells patient 1# (B), patient 4# (F) and patient 5# (J). Drug synergy index at different concentrations of Selinexor and JQ1 in different AML cells, respectively in cells patient 1# (C), patient 4# (G) and patient 5# (K). The HSA scores for these two drugs in patient 1# (D), patient 4# (H) and patient 5# (L). (M-O) Expression levels of C-MYC at different concentrations of Selinexor and JQ1 in patient 1# (M), patient 4# (N) and patient 5# (O) at 24 h. All experiments were performed with at least three independent replicates